Association of adipokines and inflammatory markers with lipid control in type 2 diabetes

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 6, 2015, Pages 414-423

  Kapłon Cies̈licka, Agnieszka ^a   Postuła, Marek ^a,b   Rosiak, Marek ^b   Peller, Michał ^a   Kondracka, Agnieszka ^a   Serafin, Agnieszka ^a   Trzepla, Ewa ^a   Opolski, Grzegorz ^a   Filipiak, Krzysztof J ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Clinical Hospital of Interior   (Poland)

Author keywords

Adiponectin; Cholesterol; Necrosis factor ; Resistin; Triglycerides; Tumor

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID HOMEOSTASIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; BLOOD; INFLAMMATION; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADIPOKINES; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; LIPID METABOLISM; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84936871003     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2880     Document Type: Article

References (50)

1. Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2013; 34: 3035-3087.
2. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012; 33: 1635-1701.
3. American Diabetes Association. Standards of Medical Care in Diabetes - 2014. Diabetes Care. 2014; 37: S14-S80.
4. Li ZY, Wang P, Miao CY. Adipokines in inflammation, insulin resistance and cardiovascular disease. Clin Exp Pharmacol Physiol. 2011; 38: 888-896.
5. Kukla M, Zwirska-Korczala K, Hartleb M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010; 45: 235-242.
6. Kumor-Kisielewska A, Kierszniewska-Stepien D, Pietras T, et al. Assessment of leptin and resistin levels in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2013; 123: 215-220.
7. Ziora D, Machura E, Ziora KT, et al. Serum resistin levels are elevated in schoolchildren with atopic asthma. Neuro Endocrinol Lett. 2013; 34: 212-216.
8. Kontny E, Plebanczyk M, Lisowska B, et al. Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinflammatory stimuli: contribution to adipocytokine network. Ann Rheum Dis. 2012; 71: 262-267.
9. Kukla M, Mazur W, Bułdak RJ, et al. Potential role of leptin, adiponectin and three novel adipokines - visfatin, chemerin and vaspin - in chronic hepatitis. Mol Med. 2011; 17: 1397-1410.
10. Al-Daghri N, Chetty R, McTernan PG, et al. Serum resistin is associated with C-reactive protein and LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc Diabetol. 2005; 4: 10.
11. De Luis DA, Sagrado MG, Conde R, et al. Relation of resistin levels with cardiovascular risk factors, insulin resistance and inflammation in naïve diabetes obese patients. Diabetes Res Clin Pract. 2010; 89: 110-114.
12. Uslu S, Kebapçi N, Kara M, et al. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med. 2012; 4: 113-120.
13. Cabrera de León A, Almeida González D, González Hernández A, et al. Relationships between serum resistin and fat intake, serum lipid concentrations and adiposity in the general population. J Atheroscler Thromb. 2014; 21: 454-462.
14. Malo E, Ukkola O, Jokela M, et al. Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish Health 2000 survey. Metab Syndr Relat Disord. 2011; 9: 203-210.
15. Fisman EZ, Tenenbaum A. Adiponectin: A manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014; 13: 103.
16. Bik W, Baranowska-Bik A, Wolinska-Witort E, et al. Assessment of adiponectin and its isoforms in Polish centenarians. Exp Gerontol. 2013; 48: 401-407.
17. Tschritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003; 52: 239-243.
18. Katsuki A, Sumida Y, Urakawa H, et al. Plasma levels of adiponectin are associated with insulin resistance and serum levels of triglyceride in Japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Care. 2003; 26: 2964-2965.
19. Postula M, Kaplon-Cieslicka A, Rosiak M, et al. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: Evaluation of 27 polymorphisms within candidate genes. J Thromb Haemost. 2011; 9: 2291-2301.
20. Kapłon-Cieslicka A, Rosiak M, Postuła M, et al. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. Kardiol Pol. 2013; 71: 893-902.
21. Howards PP, Schisterman EF, Poole C, et al. "Toward a clearer definition of confounding" revisited with directed acyclic graphs. Am J Epidemiol. 2012; 176: 506-511.
22. Kushiyama A, Shojima N, Ogihara T, et al. Resistin-like molecule beta activates MAPKs, suppresses insulin signaling in hepatocytes, and induces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a high fat diet. J Biol Chem. 2005; 280: 42016-42025.
23. Piestrzeniewicz K, Łuczak K, Komorowski J, et al. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism. 2008; 57: 488-493.
24. Zheng H, Xu H, Xie N, et al. Association of serum resistin with peripheral arterial disease. Pol Arch Med Wewn. 2013; 123: 680-685.
25. Melone M, Wilsie L, Palyha O, et al. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol. 2012; 59: 1697-1705.
26. Owecki M, Nikisch E, Miczke A, et al. Serum resistin is related to plasma HDL cholesterol and inversely correlated with LDL cholesterol in diabetic and obese humans. Neuro Endocrinol Lett. 2010; 31: 673-678.
27. Liu Y, Wang Q, Pan YB, et al. Effects of over-expressing resistin on glucose and lipid metabolism in mice. J Zhejiang Univ Sci B. 2008; 9: 44-50.
28. Kushiyama A, Sakoda H, Oue N, et al. Resistin-like molecule β is abundantly expressed in foam cells and is involved in atherosclerosis development. Arterioscler Thromb Vasc Biol. 2013; 33: 1986-1993.
29. Rae C, Graham A. Human resistin promotes macrophage lipid accumulation. Diabetologia. 2006; 49: 1112-1114.
30. Jové M, Planavila A, Cabrero A, et al. Reductions in plasma cholesterol levels after fenofibrate treatment are negatively correlated with resistin expression in human adipose tissue. Metabolism. 2003; 52: 351-355.
31. Sanip Z, Ariffin FD, Al-Tahami BA, et al. Obesity indices and metabolic markers are related to hs-CRP and adiponectin levels in overweight and obese females. Obes Res Clin Pract. 2013; 7: E315-e320.
32. Rubin DA, McMurray RG, Hackney AC, et al. Relationship between cardiovascular risk factors and adipokines in adolescents. Horm Res Paediatr. 2011; 76: 123-129.
33. Chan DC, Watts GF, Ng TW, et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem. 2005; 51: 578-585.
34. Maruyama C, Ishibashi R, Araki R, et al. HMW-adiponectin associates with triglyceride concentrations in type 1 diabetic patients. J Atheroscler Thromb. 2009; 16: 207-216.
35. Ng TW, Watts GF, Farvid MS, et al. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes. 2005; 54: 795-802.
36. Qiao L, Zou C, van der Westhuyzen DR, et al. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes. 2008; 57: 1824-1833.
37. Oguro R, Kamide K, Katsuya T, et al. A single nucleotide polymorphism of the adenosine deaminase, RNA-specific gene is associated with the serum triglyceride level, abdominal circumference, and serum adiponectin concentration. Exp Gerontol. 2012; 47: 183-187.
38. Amezaga Urruela M, Suarez-Almazor ME. Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies. Curr Rheumatol Rep. 2012; 14: 428-437.
39. Ettinger WH, Varna VK, Sorci-Thomas M, et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb. 1994; 14: 8-13.
40. Field FJ, Watt K, Mathur SN. TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2. J Lipid Res. 2010; 51: 1407-1415.
41. Keidar S, Gilhar A, Kaplan M, et al. Enhanced degradation of high density lipoprotein by peritoneal macrophages from nude mice is attenuated by interleukin-1. Artery. 1993; 20: 268-279.
42. Casas AT, Hubsch AP, Rogers BC, et al. Reconstituted high-density lipoprotein reduces LPS-stimulated TNF alpha. J Surg Res. 1995; 59: 544-552.
43. Yamagishi S, Adachi H, Matsui T, et al. Decreased high-density lipoprotein cholesterol level is an independent correlate of circulating tumor necrosis factor-alpha in a general population. Clin Cardiol. 2009; 32: E29-E32.
44. Van Eijk IC, de Vries MK, Levels JH, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis. Arthritis Rheum. 2009; 60: 1324-1330.
45. Jamnitski A, Levels JH, van den Oever IA, et al. High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: A cohort study. J Rheumatol. 2013; 40: 825-830.
46. Irace C, Mancuso G, Fiaschi E, et al. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis. 2004; 177: 113-118.
47. Pradhan AD. Sex differences in the metabolic syndrome: implications for cardiovascular health in women. Clin Chem. 2014; 60: 44-52.
48. Virani SS, Woodard LD, Chitwood SS, et al. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am Heart J. 2011; 162: 725-732.
49. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: Results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010; 121: 1069-1077.
50. Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother. 2014; 5: 181-185.